Heartbeam (BEAT) vs Cytosorbents (CTSO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Heartbeam (BEAT) has outperformed Cytosorbents (CTSO) over the past year, losing 64.8% versus a loss of 70.6%. Over five years, BEAT leads with a -92.9% price change compared with -95.6% for CTSO. Heartbeam is the larger company by market cap ($17.4 million vs $13.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAT | CTSO |
|---|---|---|
| Share price | $0.2751 | $4.16 |
| Market cap | $17.42M | $13.12M |
| 1-day change | -10.94% | -18.91% |
| YTD return | -88.54% | -67.45% |
| 1-year return | -64.78% | -70.58% |
| 5-year return | -92.89% | -95.62% |
| EPS (TTM) | $-0.39 | $-5.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $37.06M |
| Revenue growth (YoY) | — | +4.12% |
| Net income (latest FY) | $-21.02M | $-8.20M |
| Gross margin | — | 71.48% |
| Operating margin | — | -39.79% |
| Net margin | — | -22.12% |
| 52-week high | $4.00 | $17.00 |
| 52-week low | $0.2727 | $2.84 |
| Distance from 52-week high | -93.12% | -75.53% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1172.26% | +1041.83% |
| Average volume | 7.50M | 37.34K |
| Shares outstanding | 63.31M | 3.15M |
| Employees | 16 | 129 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Heartbeam
BEAT stock →HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility.
Health Care · Medical/Dental Instruments · 16 employees
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Health Care · Medical/Dental Instruments · 129 employees
BEAT vs CTSO FAQ
Which is bigger, Heartbeam or Cytosorbents?
Heartbeam (BEAT) is larger, with a market capitalization of $17.42M compared with $13.12M for Cytosorbents (CTSO).
Which stock has performed better over the past year, BEAT or CTSO?
BEAT returned -64.78% over the past 12 months, compared with -70.58% for CTSO (price return, excluding dividends). Past performance does not predict future results.
Are Heartbeam and Cytosorbents in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.